Roche Holding AG Shares Outstanding 2006-2019 | RHHBY

Roche Holding AG shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Roche Holding AG shares outstanding for the quarter ending December 31, 2019 were M, a NAN% increase year-over-year.
  • Roche Holding AG 2019 shares outstanding were 6.912B, a 0.47% increase from 2018.
  • Roche Holding AG 2018 shares outstanding were 6.88B, a 0% decline from 2017.
  • Roche Holding AG 2017 shares outstanding were 6.88B, a 0% decline from 2016.
Roche Holding AG Annual Shares Outstanding
(Millions of Shares)
2019 6,912
2018 6,880
2017 6,880
2016 6,880
2015 6,897
2014 6,906
2013 13,808
2012 13,676
2011 6,807
2010 7,035
2009 6,905
2008 4,158
2007 4,027
2006 4,053
2005
Roche Holding AG Quarterly Shares Outstanding
(Millions of Shares)
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
2008-12-31
2008-06-30
2007-12-31
2007-09-30 406
2007-06-30
2006-12-31
2006-06-30
2005-12-31
2005-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.019B $61.869B
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.183B 18.45
Merck (MRK) United States $207.145B 14.78
Pfizer (PFE) United States $200.992B 12.56
Novartis AG (NVS) Switzerland $199.208B 15.49
Novo Nordisk (NVO) Denmark $165.354B 26.90
AbbVie (ABBV) United States $153.346B 9.34
AstraZeneca (AZN) United Kingdom $144.629B 28.12
Eli Lilly (LLY) United States $139.893B 21.35
Sanofi (SNY) $126.459B 15.03
GlaxoSmithKline (GSK) United Kingdom $93.894B 12.31
Bayer (BAYRY) Germany $58.490B 8.43
H Lundbeck (HLUYY) Denmark $6.527B 11.34
Innoviva (INVA) United States $1.047B 5.01